BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating [Yahoo! Finance]
Recursion Pharmaceuticals, Inc. - Class A (RXRX)
Company Research
Source: Yahoo! Finance
a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) but lowered the price target from $7 to $6. ?The firm said in a research note that the company has yet to prove that its AI-driven operating system can reliably generate differentiated drug candidates and meaningful patient outcomes. BofA noted that Recursion can do this through repeated wins in clinical trials. The firm highlighted that FAP data readout for REC-4881 is a solid start; however, the clinical data from the program is expected to materialize in 2027. ?BofA noted that the company's cash burn discipline and partnership remain positive components, but upcoming pipeline readouts are considered the main catalysts for building more confidence in the market. BoFA Lowers PT on Recursion Pharmaceuticals (RXRX), Keeps a Hold Rating ?Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) operates as a clinical-stage biotechnology company that decodes biology and chemistry by integrating technological innovations across bio
Show less
Read more
Impact Snapshot
Event Time:
RXRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RXRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RXRX alerts
High impacting Recursion Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RXRX
News
- Jim Cramer on Recursion Pharmaceuticals: “It's a Let Down, Big Let Down” [Yahoo! Finance]Yahoo! Finance
- Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1-Year Share Slump Accurately [Yahoo! Finance]Yahoo! Finance
- Recursion's First AI Clinical Proof Links Pipeline Progress With Valuation Gap [Yahoo! Finance]Yahoo! Finance
- What Makes Recursion Pharmaceuticals (RXRX) So Attractive [Yahoo! Finance]Yahoo! Finance
- Can This AI Stock Bounce Back in 2026? [Yahoo! Finance]Yahoo! Finance
RXRX
Earnings
- 2/25/26 - Beat
RXRX
Sec Filings
- 3/17/26 - Form 144
- 3/11/26 - Form 4
- 3/11/26 - Form 4
- RXRX's page on the SEC website